MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
2.020
-0.020 (-0.98%)
At close: Dec 20, 2024, 4:00 PM
1.960
-0.060 (-2.97%)
After-hours: Dec 20, 2024, 7:50 PM EST
Company Description
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312 416 8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 25, 2024 | SC 13D | General statement of acquisition of beneficial ownership |